{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:07:39Z","timestamp":1771650459923,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.dsx.2022.102498","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T03:51:55Z","timestamp":1652413915000},"page":"102498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of linagliptin on cardiovascular risk and cardiometabolic parameters in Thai patients with type 2 diabetes mellitus: A real-world observational study"],"prefix":"10.1016","volume":"16","author":[{"given":"Natnicha","family":"Poonchuay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konkanok","family":"Wattana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3943-4896","authenticated-orcid":false,"given":"Suriyon","family":"Uitrakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2022.102498_bib1","series-title":"IDF diabetes atlas","year":"2019"},{"issue":"7533","key":"10.1016\/j.dsx.2022.102498_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/bmj.38678.389583.7C","article-title":"Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies","volume":"332","author":"Huxley","year":"2006","journal-title":"BMJ"},{"issue":"Suppl 2","key":"10.1016\/j.dsx.2022.102498_bib3","article-title":"Mortality and causes of death in the WHO multinational study of vascular disease in diabetes","volume":"44","author":"Morrish","year":"2001","journal-title":"Diabetologia"},{"issue":"14","key":"10.1016\/j.dsx.2022.102498_bib4","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.dsx.2022.102498_bib5","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.dsx.2022.102498_bib6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.dsx.2022.102498_bib7","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/dom.12548","article-title":"Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17000 patients","volume":"17","author":"McInnes","year":"2015","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2022.102498_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1475-2840-11-3","article-title":"Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme","volume":"11","author":"Johansen","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.dsx.2022.102498_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-015-0215-2","article-title":"Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events","volume":"14","author":"Rosenstock","year":"2015","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.dsx.2022.102498_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.dsx.2022.102498_bib11","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.dsx.2022.102498_bib12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials","volume":"11","author":"Gilbert","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.dsx.2022.102498_bib13","series-title":"Clinical practice guideline for diabetes","author":"Diabetes Association of Thailand","year":"2017"},{"issue":"2","key":"10.1016\/j.dsx.2022.102498_bib14","first-page":"93","article-title":"Comparison of cardiovascular risk estimation tools in Thai hospital employees","volume":"17","author":"Sukontasarn","year":"2021","journal-title":"BKK Med J"},{"key":"10.1016\/j.dsx.2022.102498_bib15","series-title":"ASCVD risk estimator plus","author":"American College of Cardiology","year":"2021"},{"issue":"25 Suppl 2","key":"10.1016\/j.dsx.2022.102498_bib16","first-page":"S49","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.dsx.2022.102498_bib17","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","article-title":"Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors","volume":"122","author":"Scheen","year":"2018","journal-title":"Circ Res"},{"issue":"11","key":"10.1016\/j.dsx.2022.102498_bib18","first-page":"e596","article-title":"ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology\/American heart association Task Force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.dsx.2022.102498_bib19","doi-asserted-by":"crossref","first-page":"102437","DOI":"10.1016\/j.dsx.2022.102437","article-title":"Efficacy of vildagliptin on 10-year cardiovascular risk reduction in Thai patients with type 2 diabetes mellitus: a real-world observational study","volume":"16","author":"Wattana","year":"2022","journal-title":"Diabetes Metabol Syndr"},{"issue":"7","key":"10.1016\/j.dsx.2022.102498_bib20","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/dom.13995","volume":"22","author":"Cooper","year":"2020","journal-title":"Diabetes Obes Metabol"},{"issue":"2","key":"10.1016\/j.dsx.2022.102498_bib21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/dom.14254","article-title":"Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: a subgroup analysis of the randomized CAROLINA trial","volume":"23","author":"Espeland","year":"2021","journal-title":"Diabetes Obes Metabol"},{"issue":"8","key":"10.1016\/j.dsx.2022.102498_bib22","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2337\/dc20-0279","article-title":"Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial","volume":"43","author":"Perkovic","year":"2020","journal-title":"Diabetes Care"},{"issue":"16","key":"10.1016\/j.dsx.2022.102498_bib23","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s40265-014-0308-3","article-title":"Linagliptin: an update of its use in patients with type 2 diabetes mellitus","volume":"74","author":"McKeage","year":"2014","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.dsx.2022.102498_bib24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1161\/CIRCOUTCOMES.115.002436","article-title":"Is isolated low high-density lipoprotein cholesterol a cardiovascular disease risk factor? New insights from the Framingham offspring study","volume":"9","author":"Bartlett","year":"2016","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122001126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122001126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:18:03Z","timestamp":1761729483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402122001126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1871402122001126"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102498","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of linagliptin on cardiovascular risk and cardiometabolic parameters in Thai patients with type 2 diabetes mellitus: A real-world observational study","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102498","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102498"}}